Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Christopher Rumplik

Physician Assistant Agawam, MA Physician Assistant

NPI 1144847286 CMS profile 11177014

200 Silver St Unit 106, Agawam, MA 01001

Open in the dashboard

General payments

$14,599

621 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Christopher Rumplik of Agawam, MA is reported in the CMS Open Payments database as having received $14,599 across 621 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,172 238
2024 General $5,874 252
2023 General $3,509 129
2021 General $43 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Christopher Rumplik
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Christopher Rumplik were reported at $5,172. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Christopher Rumplik Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $43 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $3,509 $167 $52–$557 $160
2024 $5,874 $178 $55–$600 $164
2025 $5,172 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,300 104 payments
  2. E.R. Squibb & Sons, L.L.C. $1,541 64 payments
  3. Janssen Biotech, Inc. $1,330 35 payments
  4. UCB, Inc. $1,234 84 payments
  5. Arcutis Biotherapeutics, Inc. $1,026 53 payments
  6. Lilly USA, LLC $931 32 payments
  7. Novartis Pharmaceuticals Corporation $821 50 payments
  8. Incyte Corporation $793 30 payments
  9. Sun Pharmaceutical Industries Inc. $764 29 payments
  10. Genzyme Corporation $592 13 payments
  11. Other $3,266 127 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,007 613 payments
  2. Education $591 8 payments
Products named General payments · program years 2021–2025
  1. SOTYKTU $1,541 64 payments
  2. TREMFYA $1,330 35 payments
  3. RINVOQ $1,263 40 payments
  4. Bimzelx $1,090 69 payments
  5. DUPIXENT $892 18 payments
  6. OPZELURA $793 30 payments
  7. COSENTYX $752 46 payments
  8. Zoryve $738 43 payments
  9. SKYRIZI $675 31 payments
  10. TALTZ $663 24 payments
  11. Other $6,238 284 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

675

Median for Physician Assistant: 241

Drug cost

$130,763

Median for Physician Assistant: $4,110

Branded share of claims

4.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 30 $113,904
Tacrolimus Generic 56 $3,367
Fluorouracil Generic 67 $3,321
Clobetasol Propionate Generic 20 $1,345
Pimecrolimus Generic 12 $1,146
Fluocinolone Acetonide Generic 17 $1,120
Doxycycline Monohydrate Generic 70 $1,114
Ketoconazole Generic 78 $990
Triamcinolone Acetonide Generic 131 $896
Metronidazole Generic 14 $667

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$49,849

Of which drugs: $33

Medicare patients

348

Average age 74

Services billed

1,356

123 women, 225 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 39%
Ischemic heart disease 28%
Diabetes 25%
Chronic kidney disease 23%
Atrial fibrillation 22%
Depression 18%
Cancer 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 11 40 $33

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SOTYKTU
$745 — —
RINVOQ
$658 — —
Bimzelx
$577 — —
TREMFYA
$430 — —
Zoryve
$374 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

621 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record